Non-AI organisations won't make it to 2050, says Diogo Rau

Eli Lilly's Diogo Rau emphasizes the critical role of AI in the pharmaceutical industry's future, predicting that companies not investing in AI now may not survive by 2050. Rau highlights AI's potential in drug discovery, including designing proteins and identifying promising molecules. He notes the challenge of limited datasets and the importance of negative results in training AI models.